Positive Phase 3 Results for Novel Schizophrenia Drug

The investigational agent xanomeline-trospium (KarXT, Karuna Therapeutics), which combines a muscarinic receptor agonist with an anticholinergic agent, helps improve psychosis symptoms, and is not associated with weight gain or sedation in adults with schizophrenia, new research shows. Top-line results from the phase 3 EMERGENT-2 trial showed a significantly greater reduction from baseline on Positive and … Read more

Novel Drug ‘Promising’ for Concomitant Depression, Insomnia

The novel antidepressant seltorexant (Janssen Pharmaceuticals) may be beneficial for patients with concomitant major depressive disorder (MDD) and sleep disturbance, new research suggests. In a randomized, placebo-controlled, adaptive dose-finding study conducted in more than 200 patients with MDD, those with more severe insomnia at baseline had a greater improvement in depressive symptoms vs those with … Read more

Antipsychotic Safe, Effective for Resistant Depression

Cariprazine (Vraylar) is a safe and effective adjunctive treatment for adults with major depressive disorder (MDD) who have an inadequate response to antidepressant monotherapy, new results from a phase 3 study show. Already approved by the US Food and Drug Administration (FDA) to treat adults with schizophrenia and manic, mixed, or depressive episodes of bipolar … Read more

A Novel Target in Schizophrenia?

AUT00206, a novel compound that targets potassium channels in brain interneurons, not only improves gamma oscillations in patients with schizophrenia, it also improves their symptoms, new randomized trial data suggest. In a randomized, double-blind study that included two dozen men with schizophrenia, AUT00206 compared with placebo increased the power of gamma oscillations, which were in … Read more

Sublingual Dexmedetomidine May Rapidly Calm Bipolar Agitation

An investigational, orally dissolving formulation film of dexmedetomidine (BXCL501, BioXcel Therapeutics) can rapidly relieve mild to moderate acute agitation in patients with bipolar disorder (BD), new research suggests. The phase 3 SERENITY II trial included almost 400 adults with bipolar I or II disorder and acute agitation. Results showed relief from acute agitation kicked in … Read more